Products
Ingitamig Biosimilar Bispecific Antibody (BCMA × NKG2D) for Research
Cat No.: GMP-Bios-INN-1238
Anti-TNFRSF17/CD269/BCMA/TNFRSF13A therapeutic antibody (Pre-made Ingitamig biosimilar,Bispecific Mixed mAb and tandem mAb/scFv) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Ingitamig (development codes BMS-986392/DF3001) is a bispecific antibody targeting BCMA (TNFRSF17) and NKG2D (KLRK1). It is developed by Bristol Myers Squibb and Dragonfly Therapeutics for multiple myeloma. It is in Phase I clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1238-1mg | 1mg | |
| GMP-Bios-INN-1238-10mg | 10mg | |
| GMP-Bios-INN-1238-100mg | 100mg | |
| GMP-Bios-INN-1238-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Ingitamig biosimilar, Bispecific Mixed mAb and tandem mAb/scFv, Anti-TNFRSF17/CD269/BCMA/TNFRSF13A;KLRK1/NKG2D/CD314 Antibody: Anti-TNFRSF17/BCMA/CD269/Tumor necrosis factor receptor superfamily member 17 therapeutic antibody |
| INN Name | Ingitamig |
| Target | TNFRSF17/CD269/BCMA/TNFRSF13A;KLRK1/NKG2D/CD314 |
| Format | Bispecific Mixed mAb and tandem mAb/scFv |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1;G1 |
| VD LC | Kappa;Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2024 |
| Year Recommended | na |
| Companies | Dragonfly Therapeutics;Celgene Corporation;Bristol Myers Squibb |
| Conditions Approved | na |
| Conditions Active | Multiple myeloma |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
